Industry Leader

Optimism For Life Sciences Growth Amid Policy Shifts In 2025

EY's Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.

Burn Out Or Busting Out

There is no clear metric for measuring a biopharmaceutical organization's energy. However, leaders that direct, create, and conserve energy can enhance employee wellbeing and improve business performance, explains Ron Cooper.

The Power of Putting People First in Driving Business Growth

Happy workers drive high performing businesses. Biopharma executive John Harlow shares five tips for adopting a people-first mindset and other strategies for meaningful engagement with colleagues.

Five Lessons For Creating The Drug Development Leaders Of Tomorrow

Inspiring and nurturing the drug development leaders of tomorrow throughout their school years, early work experiences, and their careers helps patients, companies, and society at large. AstraZeneca's Renee Iacona provides the how and why.

How Prioritizing OpEx Can Raise Sinking Biopharma Valuations

As investment in the life sciences industry decreases, young companies struggle to keep the lights on. Young companies may overcome these challenges by implementing operational excellence (OpEx) early on in drug development rather than waiting until manufacturing startup.

From Robotics To AI … Yesterday's Unknown Is Tomorrow's Promise

As part of my professional consulting and patient advocacy work in healthcare, I have learned about AI and seen first-hand the difference it is already making for countless patients and physicians around the world.

Why Founder CEOs Deliver In Bear Markets

Downturns like the current one highlight the need to move from an industry built for the next exit to one that’s built to benefit patients by prioritizing the best science and sustainable drug innovation.

How IT Can Drive Life Sciences Innovation

Here are three ways biotech companies and research universities can better balance IT demands with researchers’ needs.

Can We Accelerate Biosimilars Development Without Compromising Quality Or Safety?

What can we do to accelerate biosimilars’ path to market without compromising quality or safety? While clinical changes would likely take years, if not decades, to implement, innovations in CMC protocols may provide near-term solutions.

My Path From The Clinic, To Research, To Biotech Leadership

I never thought I would leave academia. However, “a knock” on my career door presented me with an opportunity to join a biotech company with cell-free DNA testing. I considered my options carefully, spoke with family and mentors, and made the leap earlier this year.